NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07407140 2026-03-02
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06656598 2026-02-11
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07372365 2026-01-28
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07207824 2025-10-06
HERO
Fudan University
Phase 3 Not yet recruiting
NCT07199855 2025-09-30
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
Phase 2 Active not recruiting
NCT05051631 2025-08-28
BRAVE
Vanderbilt University Medical Center
Phase NA Completed
NCT07014202 2025-07-30
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07094464 2025-07-30
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended